Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | PROMISE: why early detection of MGUS is vital to reducing MM incidence

Irene Ghobrial, Kenneth Anderson and Robert Kyle • 14 Sep 2019
IMW 2019
Multiple Myeloma
PROMISE

Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, and Robert Kyle, MD, Mayo Clinic, Rochester, MN, here discuss the PROMISE study in a roundtable meeting at the International Myeloma Workshop (IMW) 2019, in Boston, MA. They highlight why detecting MGUS is crucial to reducing the instance of progression to MM, and how the PROMISE study will be influential in the future of myeloma-related screening program development.

More from Irene Ghobrial

Risk stratification in smoldering myeloma: current standards and emerging advances 1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025
Controversies and unanswered questions in smoldering myeloma and MGUS 0:53
Controversies and unanswered questions in smoldering myeloma and MGUS
Irene Ghobrial • 17 Sep 2025
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors 0:51
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors
Irene Ghobrial • 17 Sep 2025
Wrap-up of the 2025 Intercepting Blood Cancers Workshop 0:50
Wrap-up of the 2025 Intercepting Blood Cancers Workshop
Irene Ghobrial • 13 Mar 2025

More from Kenneth Anderson

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Francesco Maura et al. • 4 Nov 2024
Collaboration in the myeloma community 1:27
Collaboration in the myeloma community
Kenneth Anderson • 14 May 2022
The future of myeloma treatment and the possibility of cure 4:04
The future of myeloma treatment and the possibility of cure
Kenneth Anderson • 14 May 2022

More from Robert Kyle

MGUS, smoldering myeloma & the need to monitor patients 2:11
MGUS, smoldering myeloma & the need to monitor patients
Robert Kyle • 19 Apr 2018
Clinical significance of smoldering myeloma 1:16
Clinical significance of smoldering myeloma
Robert Kyle • 19 Apr 2018
150 years of multiple myeloma therapy 4:57
150 years of multiple myeloma therapy
Robert Kyle • 19 Apr 2018
Promising new therapies for MM treatment 1:08
Promising new therapies for MM treatment
Robert Kyle • 19 Apr 2018

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals